How safe are anticholinergics in patients with COPD?
Guidance for clinicians on how to interpret conflicting evidence from recent studies.
Mark J
MJ
Hew
Piersante
P
Sestini
Louis B
LB
Irving
D002318:Cardiovascular Diseases / Q000453:epidemiology; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000453:epidemiology; D012107:Research Design; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000009:adverse effects*; D000069447:Tiotropium Bromide
D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D009241:Ipratropium; D000069447:Tiotropium Bromide